Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Apr 3;10(1):5886.
doi: 10.1038/s41598-020-62618-3.

A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery

Dinesh Chandra Doval  1 , Selvi Radhakrishna  2 , Rupal Tripathi  3 , Renu Iyer Kashinath  4 , Vineet Talwar  5 , Ullas Batra  5 , Naga Amulya Mullapudi  2 , Kapil Kumar  6 , Ajay Kumar Dewan  7 , Harit Chaturvedi  8 , Juhi Tayal  9 , Anurag Mehta  10 , Sudeep Gupta  11 , Ramesh B V Nimmagadda  12
Affiliations
Multicenter Study

A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery

Dinesh Chandra Doval et al. Sci Rep. .

Abstract

The present analysis reports the clinical, pathological, treatment profile and overall survival (OS) and disease-free survival (DFS) outcomes of consecutive breast cancer patients from three Indian centres, who underwent curative surgery as their first treatment. Among the 3453 patients, stage I, II, and III cases were 11.75%, 66.79%, and 21.64%, respectively while hormone receptor positive/HER2 negative, triple negative (TNBC) and hormone receptor any/HER2 positive cases were 55.2%, 24.2% and 20.6%, respectively. The five-year OS in the entire cohort, node-negative and node-positive patients were 94.1% (93.25-94.98), 96.17% (95.2-97.15) and 91.83% (90.36-93.31), respectively, and the corresponding DFS were 88.1% (86.96-89.31), 92.0% (90.64-93.39) and 83.93% (82.03-85.89), respectively. The five-year OS in hormone receptor positive/HER2 negative, TNBC and HER2 subgroups were 96.11% (95.12-97.1), 92.74% (90.73-94.8) and 90.62% (88.17-93.15), respectively, and the corresponding DFS were 91.59% (90.19-93.02), 85.46% (82.79-88.22) and 81.29% (78.11-84.61), respectively. This is the largest dataset of early breast cancer patients from India with survival outcome analysis and can therefore serve as a benchmark for future studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Survival patterns of the whole cohort (a) Disease free survival (b) Overall survival.
Figure 2
Figure 2
Disease free survival with respect to (a) lymph node status (b) tumor size (c) hormone receptor status (d) menstrual status.
See this image and copyright information in PMC

References

    1. Becker S. A historic and scientific review of breast cancer: The next global healthcare challenge. Int. J. Gynaecol. Obstet. 2015;131(Suppl1):S36–9. doi: 10.1016/j.ijgo.2015.03.015. - DOI - PubMed
    1. Ferlay J, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Nounou MI, et al. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer. 2015;9(Suppl 2):17–34. - PMC - PubMed
    1. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J. Clin. Oncol. 2014;5(3):283–98. doi: 10.5306/wjco.v5.i3.283. - DOI - PMC - PubMed
    1. Edge, S. B. et al. AJCC Cancer Staging Manual. 7th edition. New York, Springer, 648 (2009).

Publication types

MeSH terms